Verve Therapeutics Inc.

NASDAQ: VERV · Real-Time Price · USD
11.13
0.03 (0.27%)
At close: Jul 24, 2025, 3:59 PM

Verve Therapeutics Cash Flow Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net Income
-198.71M -200.07M -157.39M -120.31M
Depreciation & Amortization
6.75M 5.46M 2.8M 1.53M
Stock-Based Compensation
43.26M 35.12M 22.48M 7.07M
Other Working Capital
-3.07M 19.68M 13.6M -9.74M
Other Non-Cash Items
-6.73M -7.75M 1.39M 35.23M
Deferred Income Tax
n/a n/a n/a 1.51M
Change in Working Capital
-2.26M 17.7M 8.38M -2.91M
Operating Cash Flow
-157.69M -149.55M -122.33M -77.88M
Capital Expenditures
-3.74M -9.28M -13.23M -4.36M
Cash Acquisitions
n/a n/a 142.72M 234.74M
Purchase of Investments
-424M -517.14M -479.4M -371.49M
Sales Maturities Of Investments
502.61M 554.11M 336.68M 136.75M
Other Investing Acitivies
n/a n/a -142.72M -234.74M
Investing Cash Flow
74.88M 27.69M -155.96M -239.1M
Debt Repayment
n/a n/a n/a n/a
Common Stock Repurchased
n/a n/a n/a n/a
Dividend Paid
n/a n/a n/a n/a
Other Financial Acitivies
2.46M 2.12M 2.46M -1.88M
Financial Cash Flow
49.2M 212.58M 328.96M 377.09M
Net Cash Flow
-33.62M 90.72M 50.67M 60.11M
Free Cash Flow
-161.43M -158.83M -135.56M -82.24M